反应停联合化疗治疗中高恶度非霍奇金淋巴瘤的临床疗效观察

Effects of thalidomide and chemotherapy in treatment of middle-high malignant non-Hodgkin's lymphoma

目的探讨反应停联合化疗治疗中高恶度非霍奇金淋巴瘤的疗效。方法采用反应停联合化疗治疗30例中高恶度非霍奇金淋巴瘤,初发患者22例,复发患者8例。其中:中恶度24例,18例为初发患者,复发性6例;高恶度6例,4例为初发患者,2例为复发患者。结果:23例达完全缓解(CR76.7%,其中初发患者19例,复发4例),4例部分缓解(PR13.3%,其中初发患者2例,复发2例),总有效率为90%。结果到目前为止生存时间最长达13个月(2例),仍处于CR期。毒副作用主要为消化道症状、轻度肝功能异常以及骨髓抑制。结论反应停联合化疗治疗中高恶度非霍奇金淋巴瘤患者效果好,毒副作用较轻,值得推广使用。

Objective To elucidate the effects of thalidomide and chemotherapy in treatment of middle-high malignant non-Hodgkin's lymphoma.Methods 30 patients with middle-high malignant non-Hodgkin's lymphoma ( 24 middle malignant NHL patients,6 high malignant NHL patients)were treated with thalidomide and chemotherapy.Results The rate of complete remission was 76.7%(23/30), The rate of partial remission was 13.3%(4/30), and the overall response rate was 90.0%. Main toxicities were gastrointestinal side effects, myelosupression and neutropenia.Conclusion thalidomide and chemotherapy could be employed in treatment of the patients with middle-high malignant non-Hodgkin's lymphoma and the regimen was safe.